Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1253909-57-7
2. Icosabutate [inn]
3. Icosabutate [who-dd]
4. Prc-4016
5. Nst-4016
6. Prb-01022
7. 562599x5jl
8. 2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoic Acid
9. Butanoic Acid, 2-((5z,8z,11z,14z,17z)-5,8,11,14,17-eicosapentaen-1-yloxy)-
10. Rac-2-((5z,8z,11z,14z,17z)icosa-5,8,11,14,17-pentaen-1-yloxy)butanoic Acid
11. 2-[(5z,8z,11z,14z,17z)-5,8,11,14,17-eicosapentaen-1-yloxy]-butanoicacid
12. Icosabutate [usan:inn]
13. Unii-562599x5jl
14. Icosabutate (usan/inn)
15. Icosabutate [usan]
16. Schembl289973
17. Chembl3707220
18. Db12990
19. Hy-121212
20. Cs-0081238
21. D11211
22. Q27261360
23. 2-((5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanoic Acid
24. 2-((5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenyloxy)butanoic Acid
| Molecular Weight | 374.6 g/mol |
|---|---|
| Molecular Formula | C24H38O3 |
| XLogP3 | 6.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 17 |
| Exact Mass | 374.28209507 g/mol |
| Monoisotopic Mass | 374.28209507 g/mol |
| Topological Polar Surface Area | 46.5 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 484 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 5 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of non-alcoholic fatty liver disease including non-alcoholic steatohepatitis
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Icosabutate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Icosabutate, including repackagers and relabelers. The FDA regulates Icosabutate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Icosabutate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Icosabutate supplier is an individual or a company that provides Icosabutate active pharmaceutical ingredient (API) or Icosabutate finished formulations upon request. The Icosabutate suppliers may include Icosabutate API manufacturers, exporters, distributors and traders.
Icosabutate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Icosabutate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Icosabutate GMP manufacturer or Icosabutate GMP API supplier for your needs.
A Icosabutate CoA (Certificate of Analysis) is a formal document that attests to Icosabutate's compliance with Icosabutate specifications and serves as a tool for batch-level quality control.
Icosabutate CoA mostly includes findings from lab analyses of a specific batch. For each Icosabutate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Icosabutate may be tested according to a variety of international standards, such as European Pharmacopoeia (Icosabutate EP), Icosabutate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Icosabutate USP).
LOOKING FOR A SUPPLIER?
